In the DESTINY-Breast09 trial, presented at this year's American Society of Clinical Oncology (ASCO) annual meeting, first-line trastuzumab deruxtecan (T-DXd; Enhertu) combined with pertuzumab ...

Dr. Mabel Mardones educates patients on breast cancer subtypes, as well as treatment options for those with ER-positive, HER2 ...

In one study looking at HER2-positive patients whose cancer had spread outside the breast, researchers found that the cancer was no longer overproducing HER2 in 1 in 4 patients. The chance of ...

“ZW25 has demonstrated appealing clinical activity against HER2-positive ... information, visit www.zymeworks.com. This press release includes “forward-looking statements” within the meaning ...

I'd like to welcome one of my patients, Jocelyn Muller ... Again, these account for about 15% of breast cancers. Most HER2-amplified breast cancers will be hormone receptor-positive, meaning sensitive ...

There’s one important factor that helps determine the treatment of patients with HER2-positive metastatic breast cancer: whether breast cancer cells are hormone-receptor positive—meaning ...

“Recent clinical trials have demonstrated the benefit of combining tucatinib with trastuzumab and chemotherapy in patients with metastatic HER2 ... looking information” within the meaning ...

The trial will explore BDC-1001 monotherapy treatment in three discreet cohorts for patients with HER2-positive colorectal ... [NCT04278144] for additional information. The company is conducting ...

Envision this possible future clinical scenario: a breast cancer patient and her physicians are deciding on the best possible ...

Prior to DESTINY-Breast06, the randomized phase 3 DESTINY-Breast04 trial showed trastuzumab deruxtecan prolonged PFS and OS in patients with HER2-low unresectable and/or metastatic breast cancer ...

The Phase 1 clinical trial, currently taking place in Australia, is designed to evaluate the safety, tolerability, and preliminary efficacy of AP402 in HER2+ patients with advanced solid tumors ...